Description
OVERVIEWProduct overview
Retatrutide is a synthetic peptide designed to engage three metabolic receptors at once — GIP, GLP-1 and glucagon — rather than a single incretin pathway.
It appears in metabolic research literature examining how simultaneous receptor engagement alters glucose handling, energy expenditure and adiposity in laboratory models.
All published work is preclinical or investigational. This material is supplied as a laboratory reference compound and is not authorised as a medicine in Ireland, the UK or the EU.
SUPPLY IN IRELANDRetatrutide Ireland — supplied to research laboratories
Research groups across Ireland buy Retatrutide from Kensington Laboratories as a lyophilised Retatrutide peptide, released only against a batch-matched certificate of analysis. Every vial of high purity Retatrutide is verified by HPLC and LC-MS before it leaves the facility, so laboratories ordering Retatrutide in Ireland receive material with documented purity and identity.
Laboratory Retatrutide is packed for controlled storage and sent by tracked delivery in 3–5 days to Dublin, Cork, Galway, Limerick and the rest of Ireland. Delivery costs €9.90 per order. Teams planning Retatrutide research can review the specifications, certificate of analysis and reference list on this page before ordering.
Institutions searching for Retatrutide peptide suppliers in Ireland typically compare purity, batch documentation and delivery times. Each of those is published here: a 99% HPLC purity specification, a certificate matched to the batch code on your vial, and tracked delivery in 3–5 days.
Retatrutide is supplied strictly for laboratory research use only. It is not a medicine and is not for human or veterinary consumption.
SPECIFICATIONSProduct specifications
- Purity: ≥ 99% (HPLC)
- Appearance: White lyophilised powder
- Quantity: 5 mg or 10 mg or 15 mg or 20 mg per vial
- Peptide class: Synthetic triple GIP / GLP-1 / glucagon receptor agonist peptide
- Also known as: LY3437943, triple agonist peptide
- Solubility: Soluble in bacteriostatic or sterile water
- Storage temperature: Store at 2–8°C; long-term −20°C, protected from light
- Shelf life: 24 months lyophilised; 30 days reconstituted at 2–8°C
- Manufacturing standard: ISO 9001 facility, GMP-aligned solid-phase synthesis
- Batch information: Batch number and expiry printed on every vial label
RESEARCHResearch overview
The following summary is provided for educational and scientific context only. It describes what has been observed in published laboratory and animal studies and does not represent established clinical outcomes, medical advice or a claim of efficacy in humans.
Background
Retatrutide is a synthetic peptide designed to engage three metabolic receptors at once — GIP, GLP-1 and glucagon — rather than a single incretin pathway.
It appears in metabolic research literature examining how simultaneous receptor engagement alters glucose handling, energy expenditure and adiposity in laboratory models.
All published work is preclinical or investigational. This material is supplied as a laboratory reference compound and is not authorised as a medicine in Ireland, the UK or the EU.
Current research areas
Published investigation clusters around a small number of biological themes. Each remains experimental and none has been established as a therapeutic effect in humans.
- Incretin receptor pharmacology in cell-based assays
- Glucose handling and insulin signalling in rodent models
- Energy expenditure and adiposity endpoints
- Comparative studies against single and dual receptor agonists
Scientific context and proposed mechanisms
Study authors describe concurrent activation of GIP, GLP-1 and glucagon receptors, with the glucagon component associated in the literature with changes in energy expenditure alongside the appetite-related effects attributed to GLP-1 signalling.
Interpreting the evidence
Most published work in this area uses cell culture or rodent models with small group sizes and short observation windows. Independent replication varies considerably between compounds, and results are sensitive to species, route, dose and endpoint.
There is no regulatory-approved human protocol for this compound. Any laboratory protocol should be defined by the model under study, institutional ethical approval, appropriate controls and predefined endpoints.
References
CERTIFICATE OF ANALYSISIndependent batch testing
Every released batch is independently tested. Match the batch number on the vial to the certificate published online.
- Batch number
- KL-RETATRUTID-2405A
- Testing laboratory
- Janoshik Analytical, s.r.o.
- Date tested
- 14 May 2026
- Reported purity
- 99.14%
- Method
- RP-HPLC with UV detection at 214 nm, confirmed by LC-MS
